Table 1.
Baseline demographics and disease characteristics by treatment group in the initial 12-week studies
| Placebo (n = 879) |
Ustekinumab (n = 613) |
Brodalumab 210 mg Q2W (n = 1496) |
All brodalumab (n = 3066)a |
|
|---|---|---|---|---|
| Female, n (%) | 272 (30.9) | 196 (32.0) | 459 (30.7) | 942 (30.7) |
| Age, mean (range), years | 44.6 (18–86) | 45.1 (18–75) | 45.0 (18–75) | 44.8 (18–75) |
| Race, n (%) | ||||
| White | 799 (90.9) | 551 (89.9) | 1351 (90.3) | 2775 (90.5) |
| Asian | 29 (3.3) | 24 (3.9) | 51 (3.4) | 116 (3.8) |
| Black | 29 (3.3) | 20 (3.3) | 40 (2.7) | 85 (2.8) |
| Native Hawaiian/Pacific Islander | 3 (0.3) | 1 (0.2) | 10 (0.7) | 18 (0.6) |
| American Indian/Alaska Native | 2 (0.2) | 2 (0.3) | 8 (0.5) | 16 (0.5) |
| Other/unknown | 17 (1.9) | 15 (2.4) | 36 (2.4) | 56 (1.8) |
| Psoriasis duration, mean (range), years | 18.5 (1–67) | 18.5 (1–57) | 18.6 (1–65) | 18.4 (1–66) |
| Psoriasis area and severity index, mean (range) | 20.0 (12–66) | 20.0 (12–60) | 20.2 (12–72) | 20.2 (12–72) |
| Static physician’s global assessment score, n (%) | ||||
| 0 or 1 | 0 | 0 | 0 | 0 |
| 2 | 0 | 0 | 2 (0.1) | 8 (0.3) |
| 3 | 500 (56.9) | 345 (56.3) | 827 (55.3) | 1789 (58.3) |
| 4 | 330 (37.5) | 235 (38.3) | 583 (39.0) | 1112 (36.3) |
| 5 | 49 (5.6) | 33 (5.4) | 84 (5.6) | 157 (5.1) |
| Psoriatic arthritis, n (%) | 180 (20.5) | 114 (18.6) | 310 (20.7) | 654 (21.3) |
| Prior malignancy, n (%) | 18 (2.0) | 17 (2.8) | 34 (2.3) | 69 (2.3) |
Q2W every 2 weeks
aThe all-brodalumab group includes all patients who received ≥ 1 dose of brodalumab